Biocon Ltd’s share price fell 4.86 per cent on January 27, 2025, hitting a day’s low of Rs 369.40 on the NSE, while the NIFTY ...

Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck. Bank of America raised its price target by 9% to ₹435, reflecting ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru facility in Malaysia was classified as "Voluntary Action Indicated" ...

Biocon's shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to 'Buy' with a target price of ₹430, ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

KUALA LUMPUR, Jan 7 (Bernama) -- Biocon Biologics is committed to implementing business expansion in Malaysia. Biocon Biologics is a global company with capabilities in the development, manufacturing ...